NHS National Technology Adopt

RNS Number : 7958A

Deltex Medical Group PLC

15 October 2009

 



Deltex Medical Group plc

Update on NHS National Technology Adoption Centre (NTAC) project on the wider adoption of CardioQ-ODM™

15 October 2009 - Deltex Medical Group plc ("Deltex Medical" or "Company") today announces positive preliminary conclusions from the clinicians implementing Deltex Medical's CardioQ-ODM on a wide scale as part of NTAC's project on oesophageal Doppler monitoring ("ODM").

At the annual meeting of the European Society of Intensive Care Medicine in Vienna, Austria, doctors from the Whittington Hospital reported that, in the first phase of their implementation in 2008, they had succeeded in achieving 100% take-up of ODM in colorectal surgery and 50% adoption in orthopedic surgery. As a result, the hospital had improved the quality of care for patients by reducing post-operative complications and reduced costs by reducing lengths of hospital stay for both types of surgery. Reference ESICM abstract 0513.

Details on NTAC's ODM work are at http://www.technologyadoptionhub.nhs.uk/perioperative-fluid-management.html. NTAC expect to publish their 'How to, Why to' guide to the NHS on ODM towards the end of 2009.

Ewan Phillips, Deltex Medical's chief executive, commented:

"We expect each of the three sites working with NTAC to report successful implementation of ODM leading to substantial patient outcome and economic benefit. NTAC's work is linked to a national initiative to save one million NHS bed days a year. These preliminary findings are highly encouraging that our products can help NHS deliver this objective."

For further information, please contact:-

Deltex Medical Group plc            01243 774 837

Nigel Keen, Chairman                    [e-mail]

Ewan Phillips, Chief Executive        [e-mail]

Paul Mitchell, Finance Director       [e-mail]

Nominated Adviser & Broker

Arden Partners plc                      020 7398 1600

Chris Hardie                                  [e-mail]

Matthew Armitt                              [e-mail]

Kreab Gavin Anderson                020 7554 1400

Deborah Walter                             [e-mail]

Robert Speed                                [e-mail]

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,750 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

MSCILFVRIILSLIA